China Biologic Products Holdings, Inc. (CBPO) a plasma-based biopharmaceutical company in China, said that its majority-owned subsidiary, Shandong Taibang Biological Products Co. Ltd., recently obtained approval from the China Food and Drug Administration or CFDA to begin human clinical trials on its Human Fibrin Sealant product.
from RTT - Biotech https://ift.tt/2HDS3u9
via IFTTT
No comments:
Post a Comment